Meeder Advisory Services Inc. Invests $4.42 Million in Gilead Sciences, Inc. $GILD

Key Points

• Meeder Advisory Services initiated a $4.42 million position in Gilead Sciences by purchasing 34,965 shares during the second quarter. Institutional investors collectively own 83.67% of the company.
• Gilead reported quarterly revenue of $7.8 billion, up 10.6% year over year, and exceeded analysts’ EPS expectations despite posting a net loss. The company also declared a quarterly dividend of $0.82 per share, yielding approximately 2.3% annually.
• Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating and an average price target of $158.04. However, insiders have sold 82,000 shares worth about $10.84 million over the past 90 days, primarily under pre-arranged trading plans.

Meeder Advisory Services Inc. purchased a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the second quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 34,965 shares of the biopharmaceutical company's stock, valued at approximately $4,417,000.

Several other hedge funds have also bought and sold shares of GILD. BlackRock Inc. bought a new position in shares of Gilead Sciences during the second quarter valued at approximately $15,393,785,000. Norges Bank bought a new stake in shares of Gilead Sciences in the 4th quarter worth approximately $2,617,152,000. Deutsche Bank AG purchased a new stake in shares of Gilead Sciences in the 2nd quarter worth approximately $918,387,000. Boston Partners bought a new position in Gilead Sciences during the 4th quarter valued at approximately $517,808,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in Gilead Sciences during the second quarter valued at $398,905,000. Institutional investors own 83.67% of the company's stock.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $143.44 on Wednesday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. The firm has a market cap of $177.86 billion, a price-to-earnings ratio of -53.72 and a beta of 0.32. The business has a 50-day simple moving average of $130.69 and a two-hundred day simple moving average of $136.46. Gilead Sciences, Inc. has a fifty-two week low of $108.46 and a fifty-two week high of $157.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, topping analysts' consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The firm had revenue of $7.80 billion during the quarter, compared to analyst estimates of $7.40 billion. During the same period in the previous year, the business posted $2.01 earnings per share. The business's revenue for the quarter was up 10.6% on a year-over-year basis. On average, analysts expect that Gilead Sciences, Inc. will post -0.53 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be given a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Gilead Sciences's payout ratio is -122.85%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the business's stock in a transaction on Monday, August 17th. The shares were sold at an average price of $137.64, for a total transaction of $3,853,920.00. Following the completion of the sale, the insider directly owned 118,234 shares in the company, valued at approximately $16,273,727.76. The trade was a 19.15% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O'day sold 15,000 shares of the firm's stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $130.31, for a total value of $1,954,650.00. Following the completion of the transaction, the chief executive officer owned 592,133 shares in the company, valued at approximately $77,160,851.23. This trade represents a 2.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 82,000 shares of company stock worth $10,837,860. Insiders own 0.30% of the company's stock.

Wall Street Analyst Weigh In

GILD has been the topic of a number of recent research reports. HSBC raised Gilead Sciences from a "hold" rating to a "buy" rating and increased their target price for the stock from $133.00 to $155.00 in a research note on Monday, July 6th. Rothschild & Co Redburn dropped their price target on shares of Gilead Sciences from $170.00 to $167.00 in a research note on Monday, May 11th. Wall Street Zen raised shares of Gilead Sciences from a "hold" rating to a "buy" rating in a research report on Saturday. Truist Financial reduced their price objective on shares of Gilead Sciences from $157.00 to $156.00 and set a "buy" rating for the company in a research note on Tuesday, July 7th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $170.00 target price on shares of Gilead Sciences in a research note on Wednesday, August 5th. Twenty-four equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $158.04.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: A federal appeals court blocked companies from importing and selling cheaper foreign versions of Biktarvy in the United States. The ruling helps protect revenue from Gilead’s leading HIV treatment and removes a potential competitive and pricing threat. Gilead stock court ruling on Biktarvy imports
• Positive Sentiment: Gilead’s HIV franchise remains the primary growth engine. Biktarvy continues to lead treatment, while the newer Yeztugo product and additional pipeline programs could expand the company’s prevention and treatment opportunities. Is Gilead's Expanding HIV Portfolio a Growth Catalyst?
• Positive Sentiment: Commentary from The Motley Fool highlighted Gilead as an underappreciated healthcare turnaround story, citing double-digit quarterly revenue growth, strong HIV sales, acquisitions, and an expanding oncology portfolio. This supports investor optimism about longer-term diversification beyond HIV. Gilead Sciences turnaround story
• Neutral Sentiment: Gilead is participating in a highly competitive antibody-drug conjugate oncology market. The company’s technology and patent position may create future opportunities, but the landscape also involves substantial competition and development risk. Cancer and antibody-drug conjugates patent landscape
• Negative Sentiment: Chief Commercial Officer Johanna Mercier sold 28,000 shares worth approximately $3.85 million. Because the transaction occurred under a pre-arranged Rule 10b5-1 plan, it is a limited signal about management’s outlook, though insider selling can still weigh modestly on sentiment.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source